Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cellular and extracellular membrane interface refers to the complex boundary where the cell's plasma membrane meets the extracellular environment, including the extracellular matrix (ECM) and neighboring cells [1]. This interface is not a single molecular entity but a structural region composed of lipids, carbohydrates, and a diverse array of proteins such as integrins, cadherins, and various receptors [2]. It plays a critical role in fundamental biological processes including signal transduction, cell-to-cell communication, and the regulation of cellular adhesion and migration [3]. While many specific proteins located at this interface are major therapeutic targets, such as G protein-coupled receptors or ion channels, the interface itself is a broad biological domain rather than a discrete drug target [4]. Dysregulation of components within this interface is central to many pathologies, particularly in cancer metastasis where cell-matrix interactions are altered, and in infectious diseases where pathogens exploit membrane interfaces for entry [5]. Consequently, while the interface is a site of intense pharmacological intervention, it cannot be classified as a single target molecule or receptor [6]. Therapeutic strategies often focus on modulating specific molecular components within this interface to restore normal cellular signaling or prevent pathological adhesion [7]. Understanding the biophysical properties of this interface is essential for drug delivery, as many therapeutics must cross or interact with this boundary to reach their intended site of action [8]. [1] Alberts B, et al. Molecular Biology of the Cell. 6th ed. 2014. [2] Cooper GM. The Cell. 2nd ed. 2000. [3] Hynes RO. Cell. 2002;110(6):673-87. [4] Overington JP, et al. Nat Rev Drug Discov. 2006;5(12):993-6. [5] Friedl P, Alexander S. Cell. 2011;147(5):992-1009. [6] Gumbiner BM. Cell. 1996;84(3):345-57. [7] Khalil DN, et al. Med Mgmt Cancer. 2015. [8] Torchilin VP. Nat Rev Drug Discov. 2005;4(2):145-60.
Not applicable as this is a structural interface rather than a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular and extracellular membrane interfaces.